THE IMPACT OF VITAMIN D ON THE ENDOTHELIUM OF RHEUMATOID ARTHRITIS PATIENTS

Mashael F. Alotaibi1; Sawsan O. Khoja1; Wesam A. Alhejily2; Sami M. Bahlas3; Alia M. Aldahlawi4,5; Mahmoud E. Gadalla6 and Mohamed F. Elshal1,7

1Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
2Cardiovascular medicine and interventional Cardiology, Faculty of medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
3Department of Internal Medicine, College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
4Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
5Immunology Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
6Department of Molecular Diagnosis, Genetic Engineering and Biotechnology Institute, University of Sadat City, Sadat city, Egypt.
7Department of Molecular Biology, Genetic Engineering and Biotechnology Institute, University of Sadat City, Sadat city, Egypt.

Running Title: Vitamin-D Impact on rheumatoid arthritis patients

Corresponding Author:
Professor Dr. Mohamed Elshal
Current address: Molecular Biology Departmen, Genetic Engineering and Biotechnology Institute, University of Sadat City, Sadat City, Egypt.
Email: Mohamed.elshal@gebri.usc.edu.eg
ORCID No.: 0000-0001-8973-6847
Researcher ID: H-7953-2012
Scopus ID: 6506130470

Key Words: Rheumatoid arthritis, vitamin D3, cardiovascular diseases, flow-mediated dilation, circulating endothelial cells, adhesion molecules, endothelial growth factor.

ABSTRACT

Background: Vitamin D is a steroid hormone that affects the expression of many genes and regulates a wide variety of cell types and organ systems, including the cardiovascular system. Patients affected by rheumatoid arthritis (RA) present with accelerated atherosclerosis and increased risk of cardiovascular disease (CVD). Aim: The aim is to evaluate the impact of vitamin-D intake on markers of vascular function in patients with RA. Methods: Forty RA with vitamin-D deficient patients were included and were supplemented with oral doses of cholecalciferol (50,000 IU) weekly...
for 8 weeks. Conventional rheumatoid measures such as DAS-28, RF, CRP and anti-MCV as well as measures of vascular functions flow-mediated dilatation (FMD) and circulating endothelial cells (CECs) and serum adhesion markers ICAM and VCAM were assessed at baseline and 8 weeks post-treatment. Forty healthy individuals were included as controls. **Results:** RA patients showed impaired FMD as compared with controls (4.28% vs 10.10%, p<0.05). Significant inverse relationships were detected between DAS-28 score and both vitamin D and FMD (r=0.437; P=0.001 and r=0.315; P=0.002 respectively). Vitamin-D intake was associated with significant improvement in FMD and lower CECs numbers. Intervention also led to significant favorable effects on inflammatory (CRP and ESR), rheumatic (RF, anti-MCV) and on circulating adhesion molecules levels (ICAM and VCAM). **Conclusion:** The present data indicate that supplementing RA with VD3 significantly improves vascular functions as indicated by enhanced FMD through a mechanism that involves regulation of adhesion molecules and inflammatory mediators.

**INTRODUCTION**

Rheumatoid arthritis (RA) is a systemic chronic autoimmune inflammatory disorder that affects approximately 1 percent of the population worldwide. It is characterized by variable autoreactivities immune cells and autoantibodies against immunoglobulin G, cartilage components, stress proteins, enzymes, nuclear proteins and citrullinated proteins causing inflammation of the lining of the joints, in a symmetric pattern. Although primarily involves the joints, RA can have a significant impact on other organ systems especially the heart and vascular system. In addition, numerous epidemiological investigations have revealed that risk of developing cardiovascular diseases (CVD) in RA patients is more than double that of the general population.

Clinical and experimental data support that inflammatory responses that accompanied immune-mediated disorders cause activation of endothelium and overexpression of key adhesion molecules involved in the recruitment of leukocytes to the endothelium. Adherence of leukocytes to endothelial cells leads to disruption of the endothelial glycocalyx and to detachment of endothelial cells into the circulation. Recently, circulating endothelial cells (CECs) have emerged as hallmarks of vascular dysfunction. CECs are present in very small numbers in healthy individuals, whereas their number increases dramatically in diseases with vascular damage, such as CVD, sepsis, vasculitis, and autoimmune diseases. Several adhesion molecules involved in this process including vascular cell adhesion molecule-1 (VCAM-1) and intracellular cell adhesion molecule-1 (ICAM-1). Leukocytes adhere to endothelium then transmigrate through it to the vascular and extravascular spaces that are central to endothelial dysfunction and the development of atherosclerotic plaques and vascular inflammatory disorders. In contrast to
healthy endothelium, dysfunctional endothelium loses its capacity of relaxation in response to mediators such as acetylcholine or to increased blood flow. Therefore, endothelial dysfunction could be detected by impaired flow-mediated dilation (FMD) \(^{21, 22}\). FMD has been suggested as a marker of the grade of atherosclerosis and may be used as a surrogate marker of cardiovascular outcomes \(^{23}\).

Many cardiovascular risk factors have been recognized. Among them, vitamin D (VD) deficiency [25(OH) D <20 ng/mL] is emerging as a novel one \(^{24, 25}\). VD is a steroid hormone that is photosynthesized mainly by skin upon the exposure to sunlight \(^{26}\). VD can also be supplemented through diet where gastrointestinal absorption takes it to blood circulation \(^{27, 28}\). In addition to its well-defined role in bone and calcium metabolism, vitamin D has been identified as an vital factor in several physiological processes, including immunity, cellular growth, and cellular differentiation \(^{29}\). VD exerts these diverse physiological functions upon binding to its nuclear receptor (VDR), a ligand-responsive transcription factor that is ubiquitously expressed in a wide variety of cell types and organ systems, including the cardiovascular system \(^{30}\). Recent studies reported the expression of VDR on vascular endothelial cells and that its interaction with VD results in the expression of hundreds of gene targets which regulate vascular cell growth, migration, and differentiation; immune response modulation; cytokine expression; and inflammatory and fibrotic pathways, all of which play a crucial role, starting from the early stage of endothelial activation/dysfunction to the later stages of the plaque vulnerability and rupture \(^{31}\).

In Saudi Arabia, the current epidemiological data indicate that vitamin D deficiency is prevalent in more than 80% of Saudi population, and it might be related to lack of adequate exposure to sunlight and inadequate consumption of dairy products \(^{32}\). Deficiency of vitamin D has been acknowledged as an independent predictor of CVD in patients with RA \(^{33-35}\). In addition, several studies have suggested that vitamin D deficiency in RA may affect inflammatory responses and endothelial functions \(^{36-38}\). These reports suggest that maintaining normal serum vitamin D levels may protect against CVD in patients with RA. To test this suggestion, and due to the lack of clinical studies on the effects of Vitamin D supplementation, we designed the current study to assess the impact of vitamin D intake on inflammatory markers, vascular functions measures and circulating endothelial adhesion molecules.

**MATERIALS AND METHODS**

**Study Design**

The present randomized cross-sectional study was carried out during the period from September 2014 and July 2015. All the patients met the 2010 American College of Rheumatology/European League Against Rheumatism (EULAR) criteria for RA classification \(^{39}\). All procedures
performed in the study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All patients who participated in the present study signed an informed consent form per the Declaration of Helsinki (October 2008). The study included two groups of subjects: group A, consists of 50 patients with RA and group B, consists of 40 healthy sex- and age-matched controls. After initial clinical assessment, patients with serum vitamin D (25(OH) D) <25 ng/mL were supplemented with oral cholecalciferol 50,000 IU per week for 8 weeks. Anthropometric data of the patients and healthy controls and clinical data were collected from the questionnaire designed for each group. The main clinical data that were collected are age, smoking, disease activity, disease duration, DAS-28 (disease activity score of 28 joints), ability of movement, vitamin D supplementations, dairy consumption, and sun’s exposure. Due to incomplete follow-up data from the hospital and absence of patients at follow-ups, the final number in group A became 40 patients.

**Blood samples**

Blood samples were withdrawn into two Ethylenediaminetetraacetic acid (EDTA) tubes. Serum was separated from one tube by centrifugation at 1500 rpm for 5 minutes. Serum samples were aliquoted in eppendorf tubes and were stored at -80 °C until analysis. The other blood tube was mixed with 5ml of Hank’s Balanced Salt Solution (HBSS), and slowly layered on top of Ficoll-Paque Premium solution (GE-Healthcare, USA) for leukocyte separation. The tubes were centrifuged at 1400 rpm, 4°C with no break for 30 minutes. The developed buffy coat was then collected and washed twice in HBSS. Leukocytes were then stored in frozen nutrient media (23% RPMI 1640 + 70% Fetal Bovine Serum + 7% Dimethylsulfoxide DMSO).

**Estimation of serum Vitamin D3**

Vitamin D3 levels were determined in the serum using 25 Hydroxy Vitamin D (25OHVD) ELISA kit (Cat. No. MBS722906, My BioSource, Inc. San Diego, CA, USA) according to the manufacturer's instructions.

**Determination of vascular function markers**

a. **FMD index assessments**

FMD is the most widely used non-invasive method to assess the endothelial function, reflecting the endothelial nitric oxide (NO) dependent vasodilation in response to occlusion-induced reactive hyperemia. FMD assessments were done using Philips iU22 high-end ultrasound machine at the Ultrasound Vascular Lab, King Abdulaziz University Hospital. This system is equipped with vascular software for two-dimensional (2D)
imaging, color and spectral Doppler, an internal electrocardiogram (ECG) monitor and a high-frequency vascular transducer. A linear array transducer with a minimum frequency of 7 MHz, attached to a high-quality mainframe ultrasound system, was used to acquire images with sufficient resolution for subsequent analysis. Images of the brachial artery were obtained for subjects after they were positioned in supine with the arm in a comfortable position for imaging. The brachial artery was imaged above the antecubital fossa in the longitudinal plane. A segment with clear anterior and posterior intimal interfaces between the lumen and vessel wall was selected for continuous 2D gray scale imaging. Percent of FMD was calculated as follows: [(post deflation diameter - resting diameter) / resting diameter] X 100.

b. CECs using Flow Cytometry (FCM)

CECs were enumerated using Flow Cytometry (FCM) as described previously. Briefly, stored BPMCs samples were thawed and washed before the addition of Anti-CD3 FITC (Cat. No. ab34275, Abcam, Cambridge, UK), CD146 [P1H12] Phycoerythrin (PE) (Cat. No. ab78488, Abcam, Cambridge, UK) and CD45 Allophycocyanin (APC) (Cat. No. ab28106, Abcam, Cambridge, UK) monoclonal antibodies antibodies. After incubation for 20 min in the dark, 5 ul of 7-Aminoactinomycin D (7-AAD) (Cat. No. ab142391, Abcam, Cambridge, UK) were added 5 minutes before analysis for exclusion of dead cells. Stained samples were then analyzed using Navios software on Gallios™ Flow Cytometer (Beckman Coulter, Inc., Miami, FL, USA). A sequential flow cytometry strategy was used for enumeration of CECs as illustrated in Figure 1.

Determination of serum adhesion markers

Adhesion molecules were determined in serum samples using ELISA kits for vascular cell adhesion molecule 1 (VCAM1, Cat. No. ab187393, Abcam, Cambridge, UK), intercellular adhesion molecule 1 (ICAM1, Cat. No. ab187403, Abcam, Cambridge, UK), vascular endothelial growth factor (VEGF, Cat. No. ab100662, Abcam, Cambridge, UK), and vascular endothelial growth factor receptor1 (VEGFR1, Cat. No. ab119567, Abcam, Cambridge, UK) according to the manufacturer's instructions.

Statistical Analysis

Statistical analysis was performed using SPSS software (version 20; SPSS Inc., Chicago, IL, USA). Values are expressed as mean ± standard deviation. The Student’s t-test was used to assess differences in tested parameters between RA patients and the control group. Pearson’s Chi-square test was used to evaluate correlations between parameters. A level of 0.05 (two-sided) was chosen to indicate statistical significance.
Figure 1: Sequential flow cytometry strategy for enumeration of CECs. CECs are defined as CD45−/CD3−/CD146+ using CD3-FITC, CD146-PE, CD45-APC conjugated antibodies. CECs: (A) Forward (FSC) and side scatter (SSC) plot of white blood cells and gating region G1 to include all mononuclear cell events while excluding platelets, dead cells, and microparticles. (B) Live cells were selected as 7AAD− events in region G2 on an Intensity 7AAD versus Intensity SSC plot gated on G1. (C) CD3 negative events were selected on cellular events from gated region G2. (D) CD146+CD45− CECs were selected in a plot gated on live single CD3− cells from G3.

RESULTS

Forty patients had completed the follow-up visit at 8 weeks after treatment. The demographic data of the patients and healthy controls were collected from the questionnaire designed for the current study and were presented. The age range was 17–86 years. Eleven out of the 51 RA patients have been excluded from the study due to incomplete follow-up data. Disease duration ranged from 6 months to 12 years with mean of 89.62±83.88 months. Three (7.5%) RA patients were smokers and 3 other patients have significant movement difficulties. No significant difference in dairy consumption or sun exposure between patients and controls. All patients have received corticosteroids previously and more than 35% of
patients were under treatment with Methotrexate and Plaquenil (DMARDs; Disease-modifying antirheumatic drugs).

Figure 2 shows that RA patients had significantly higher DAS-28 before treatment compared with controls (P<0.001). After treatment, mean DAS-28 value was lower in comparison to baseline values, however the difference was not statistically significant (P>0.05). Demonstrates the biochemical measurements and inflammatory markers of the RA patients at baseline and post-treatment with oral VD3 as compared to the reference group. At baseline, RA patients showed significantly (P<0.05) lower serum total vitamin D and serum VD3 concentrations compared with controls Both at P<0.05. Whereas after treatment with oral 50,000 IU vitamin D3 per week for 8 weeks; RA patients showed significantly higher levels of total vitamin D in comparison to their baseline values and to that of controls (p<0.05; p<0.001 respectively). After treatment, levels of serum vitamin D3 were slightly increased (p>0.05) compared with RA before treatment. The inflammatory markers CRP and ESR were found significantly lower in patients received VD3 than their baseline levels. Treatment with VD3 also reduced the rheumatic markers RF and Anti-MCV compared than that measured at baseline.

![Figure 2: Mean DAS-28 levels in RA patients before and after vitamin D treatment in comparison to controls.](image-url)
FMD of the brachial artery is an accepted procedure for non-invasive assessment of systemic endothelial function. The mean value of FMD in controls was 15.13±11.32% (median, 8.9%; IQR, 4.0–8.0%; range, 7.87–21.9%) (Figure 3A). Baseline FMD was significantly lower in RA group than in controls (6.33±6.58 vs 15.13±11.32 %, p<0.01). Post Treatment, RA group showed significant improvement in FMD compared with baseline measurements (6.33±6.58 vs 12.92±7.18 mm, p<0.05).

CECs were enumerated before and post treatment using flow cytometry as illustrated in Figure 1. Baseline CECs numbers were found significantly higher in RA group (p<0.001). CECs numbers also significantly reduced post vitamin D3 treatment compared with pre-treatment numbers. However, post-treatment CECs numbers were still significantly higher than in controls (Figure 3B).

Figure 3: Endothelial biomarkers FMD% (A) and number of CECs as measured by flow cytometry (B) in RA patients in Comparisons to controls.
The concentrations of serum endothelial growth factors and adhesion molecules of the RA patients in comparisons controls are demonstrated. Serum VEGF showed significant increase (P<0.01) at baseline and then decreased significantly (P<0.05) after 8 weeks of treatment. The soluble receptors of VEGF type 1 (sVEGFR-1) also significantly (P<0.05) decreased after treatment. Serum concentrations of adhesion molecules VCAM1 and ICAM1 also showed significant increase at baseline (both at p<0.01) in comparison to controls. After treatment a significant decrease were only recorded in VCAM1 (P<0.01) compared with their baseline values. In case of ICAM1, our patients did not show significant decrease post-treatment in comparison to baseline values.

Pearson correlations analyses revealed a significant negative correlation between DAS-28 with serum vitamin D3 (r=0.437; P=0.001) and with FMD% (r=0.315; P=0.002), while no correlation was found between DAS-28 with CECs (Figure 4A, B).

![Figure 4: Correlations of disease activity score (DAS-28) with (A) levels of serum Vitamin D3 and (B) percent of flow mediated dilation](image-url)
DISCUSSION

The pathogenesis of the chronic inflammation related rheumatic autoimmune diseases diversified greatly based on the area, the way of living, and social position suggesting that genetic and environmental factors play an essential role in occurrence and advancement of rheumatic diseases. In Saudi Arabia, the current epidemiological data indicate that overall Vitamin D deficiency is 63.5% (95% CI: 53.3, 73.7), and it might be related to lack of adequate exposure to sunlight and possibly inadequate consumption of dairy products. Several researchers have confirmed a greater occurrence of vitamin D deficiency in RA patients in comparison to healthy people. Studies also show that prevalence of vitamin D deficiency in RA and that there is an association with disease activity and cardiovascular risk factors. Therefore, it has been proposed by several research groups that vitamin D and its analogs not only can ameliorate autoimmune diseases, but also could be utilized in the management of associated vascular disorders. In the current study, the total vitamin D was measured before and after supplementation of RA patients with VD3. Post treatment with 50000 U of oral VD3 per week for 2 months, RA patients showed significant increase in total vitamin D levels (VD2 plus VD3) compared with its levels before the treatment.

Autoantibodies are frequent and characteristic aspect of rheumatic autoimmune diseases. While the greater part of autoantibodies do not appear to perform a significant pathogenetic function in these disorders, some of them have found highly beneficial as diagnostic methods and signs of disease activity. Our study revealed that the RF was significantly higher in RA group compared with healthy group. Supplementation with vitamin D significantly reduced RF quantities in both categories, suggesting Vitamin D ability to ameliorate the increase in RF associated with RA. Mutated citrullinated vimentin MCV autoantibodies are an indication of preceding damage to the joints and extreme advancement of the disease. The anti-MCV ELISA locates autoantibodies against MCV. It is a powerful and effective serological analysis for rheumatoid arthritis as it detects the disease at earliest stage, even in patients who has been recognized as negative for RF, and to some extent even prior to the appearance of certain clinical signs. Based on our data, there was a significant reduction in MCV levels after treatment with vitamin D3.

The level of disease activity in RA is frequently assessed with the Disease Activity Score of 28 Joints (DAS-28). Higher disease activity has been also involved with increased death rate, and experiments have shown that death rate is decreased by intense treatments for RA. Song et al. review the reverse relationship between disease activity in RA patients and levels of serum vitamin D. The current study is in line with Song’s
findings that supplementation of RA patients with vitamin D3 reduces the levels of DAS-28.

The studies in recent years revealed that vitamin D deficiency could influence endothelial performance. FMD of brachial arteries is a validated and useful biomarker of endothelial functionality. Harris and colleagues noticed that vitamin D3 supplements could enhance FMD in comparison to placebo users. Additionally, Malik, Giri reported that there were significant increases in %FMD in patients of myocardial infarction after vitamin D supplementation. In line with these studies, our data show enhanced FMD after vitamin D supplementation. These finding may suggest that vitamin D3 supplementations may improve endothelial performance.

Damage to endothelium has been associated with CVD morbidity and mortality in young patients with RA. Endothelial damage correspond with disease development and estimates CV activities in the normal population. CECs (CD45−CD146+) are angiogenic cells that are truly uncommon in normal individual peripheral blood and seem to be elevated in numbers in the peripheral circulation as a consequence of vascular damage or in response to vasculogenic stimulating factors. Several researches suggest that vitamin D may influence ECs indirectly through regulating inflammatory mediators on the blood vessels. In agreement with these data, the present study demonstrates that administration of VD3 was associated with significant decrease in CECs, and that decrease was concomitant with significant decrease in the inflammatory disease activity index DAS-28 and the other conventional inflammatory markers ESR, CRP and anti-MCV. In addition, it has been reported that vitamin D might reduce CVD and cardiovascular risk by regulating the production of VEGF and protecting the endothelial cells from oxidative stress through autophagic and survival pathways. It has been reported that increased levels of VEGF may result in alterations of endothelial functions, which may subsequently trigger the valvular remodelling or even damage of heart valves that may leads to rheumatic heart diseases. Also, it has been reported that VEGF and its receptor VEGFR-1 levels are positively correlated with disease activity in RA patients. In agreement with these studies, we have observed that the levels of VEGF were significantly reduced in patients after supplementation with vitamin D3, confirming the role of VD3 in regulating VEGF production. The integrins or the adhesion molecules (ICAM1 and VCAM1) also appeared to have important roles in development of rheumatic heart disease as it were found associated with valvular lesion, cardiac muscle cell death and heart failure. ICAM and VCAM adhesion molecules belong to a subgroup of Ig-like superfamily gene that is secreted from the endothelium. The secretion of these molecules was found positively associated with endothelial cell damage and endothelial activation and cause
adhesion of leukocytes to the vascular membrane and escalation of the atherosclerotic process \(^9,61\). In the present study the concentrations of serum integrins were found significantly higher in RA patients at baseline. However, their concentrations were reduced dramatically post-treatment with oral VD3. Our results are comparable to that of Naeini, Moeinzadeh \(^62\) who found that administration of 50,000 IU Vitamin D orally per week for 8 weeks in ESRD patients reduces serum levels of ICAM and VCAM which might improve the vascular condition of these patients. In summary, despite the limitations of small number of patients in this study, the preliminary results demonstrated that treatment of patients with RA with vitamin D 50,000 IU per week improved the endothelial functions as indicated by enhanced FMD and lowered numbers of CECs, VEGF and the levels of adhesion molecules ICAM-1 and VCAM-1.

**CONFLICT OF INTERESTS**

None.

**Ethics Approval**

King Abdulaziz University Research Ethics Board, Jeddah, Saudi Arabia.

**Informed consent:**

Informed consent was obtained from all individual participants included in the study.

**Acknowledgments**

The authors would like to acknowledge the King Abdulaziz City for Science and Technology KACST for funding this study.

**REFERENCES**


4. **Urman, A.; N.Taklalsingh; C. Sorrento and et al.(2018):** Inflammation beyond the Joints: Rheumatoid Arthritis and Cardiovascular Disease. *Scied J Cardiol*; 2 2019/01/05.


58. Ozgonenel, L.; E. Cetin; S. Tutun and et al. (2010): The relation of serum vascular endothelial growth factor level with disease


المرضي المصابون بالتهاب المفاصل الروماتويدي عادةً ما يعانون من تصلب الشرايين وخطر الإصابة بأمراض القلب والأوعية الدموية. أظهرت دراسات بينها في المملكة العربية السعودية أن نحو 80% مصابون بنقص فيتامين دال قد يكون بسبب عدم التعرض للشمس أو للفاكهة والفاكهة تحتوي على فيتامين دال.

الهدف من الدراسة
تقترب تناول فيتامين دال على وظائف الأوعية الدموية في مرضى الروماتويد.

المرضي والطرق المستخدمة
شملت الدراسة مجموعتين أولية من 50 مريضا بالروماتويد يعانون من نقص فيتامين دال مقارنة بمجموعة أخرى ضابطة مكونة من 50 شخصا صحيا وذلك عن طريق إعطاء فيتامين دال بتركيز 888.88 حسب الفم لمدة 8 أسابيع.

النتائج
أظهرت النتائج زيادة ملاحظة في عوامل النمو المبطنة للأوعية الدموية وجزيئات الالتحام مقارنة بالمجموعة الضابطة وذلك عن طريق الحفظ وتنظيم عمل وسائط الالتهاب.

الخلاصة
تناول فيتامين دال في المرضى المصابون بالتهاب المفاصل الروماتويدي يؤدي إلى تحسن ملحوظ في وظائف الأوعية الدموية وذلك عن طريق الحفظ وتنظيم عمل وسائط الالتهاب.